Literature DB >> 21830277

Boosting the hypoxia-induced adaptive response in inflammatory bowel disease: a novel concept of treatment.

Pieter Hindryckx1, Debby Laukens, Martine De Vos.   

Abstract

As cells critically depend on oxygen for function and survival, inadequate cellular oxygenation is a major factor in the pathogenesis of a number of life-threatening diseases. Not surprisingly, cells share adaptive mechanisms to protect them against low-oxygen conditions. The recent discovery of a new family of oxygen-dependent hydroxylases has markedly increased the understanding of these adaptive processes, which in turn has led to the identification of new therapeutic targets for the treatment of conditions associated with enhanced hypoxia, such as a number of vascular and inflammatory diseases. This mini-review focuses on inhibition of hydroxylases as a potential novel treatment option for inflammatory bowel disease. Current knowledge, as well as future directions, are summarized and discussed.
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21830277     DOI: 10.1002/ibd.21589

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  2 in total

1.  Hypoxia and Innate Immunity: Keeping Up with the HIFsters.

Authors:  Sean P Colgan; Glenn T Furuta; Cormac T Taylor
Journal:  Annu Rev Immunol       Date:  2020-01-21       Impact factor: 28.527

2.  Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis.

Authors:  Ram Gupta; Anita R Chaudhary; Binita N Shah; Avinash V Jadhav; Shitalkumar P Zambad; Ramesh Chandra Gupta; Shailesh Deshpande; Vijay Chauthaiwale; Chaitanya Dutt
Journal:  Clin Exp Gastroenterol       Date:  2014-01-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.